← Back to Clinical Trials
Recruiting NCT02815683

NCT02815683 Bronchoscopic EmphysemA Treatment in THE NetherLands

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02815683
Status Recruiting
Phase
Sponsor University Medical Center Groningen
Condition COPD
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2016-09
Primary Completion 2028-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2016-09 with a primary completion date of 2028-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Rationale: New bronchoscopic treatments for emphysema have shown promise in clinical trials, improving lung function, exercise capacity and possibly survival and are now being adopted by a number of centres in the Netherlands. It is important to ensure that the benefits seen in clinical trials are in fact reflected in clinical practice and that the best use of this early 'real world' experience is made to optimise the development and use of these novel therapies. Overall objective: to develop a national database to record bronchoscopic lung volume reduction procedures for patients with emphysema. This is desirable for audit purposes but will also be an important resource for research both in gathering data and in facilitating collaborations.

Eligibility Criteria

Inclusion Criteria: * Patient is scheduled for a bronchoscopic lung volume treatment using one-way valves. Exclusion Criteria: * There are no exclusion criteria for this study.

Contact & Investigator

Central Contact

Karin Klooster, PhD

✉ k.klooster@umcg.nl

📞 +31503616161

Principal Investigator

Dirk-Jan Slebos, MD PhD

PRINCIPAL INVESTIGATOR

University Medical Center Groningen

Frequently Asked Questions

Who can join the NCT02815683 clinical trial?

This trial is open to participants of all sexes, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02815683 currently recruiting?

Yes, NCT02815683 is actively recruiting participants. Contact the research team at k.klooster@umcg.nl for enrollment information.

Where is the NCT02815683 trial being conducted?

This trial is being conducted at Groningen, Netherlands, Maastricht, Netherlands.

Who is sponsoring the NCT02815683 clinical trial?

NCT02815683 is sponsored by University Medical Center Groningen. The principal investigator is Dirk-Jan Slebos, MD PhD at University Medical Center Groningen. The trial plans to enroll 500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology